Key points are not available for this paper at this time.
Design
Review
No takes yet. Share an insight, caveat, or question.
Supports NRG-1/ErbB as therapeutic target in cardiac disease; leaves open clinical efficacy pending prospective trials.
Rupert et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: